281 related articles for article (PubMed ID: 29109120)
1. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
[TBL] [Abstract][Full Text] [Related]
2. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
[TBL] [Abstract][Full Text] [Related]
3. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.
Vitale LA; He LZ; Thomas LJ; Widger J; Weidlick J; Crocker A; O'Neill T; Storey J; Glennie MJ; Grote DM; Ansell SM; Marsh H; Keler T
Clin Cancer Res; 2012 Jul; 18(14):3812-21. PubMed ID: 22589397
[TBL] [Abstract][Full Text] [Related]
4. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.
He LZ; Prostak N; Thomas LJ; Vitale L; Weidlick J; Crocker A; Pilsmaker CD; Round SM; Tutt A; Glennie MJ; Marsh H; Keler T
J Immunol; 2013 Oct; 191(8):4174-83. PubMed ID: 24026078
[TBL] [Abstract][Full Text] [Related]
5. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
6. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
7. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
[No Abstract] [Full Text] [Related]
8. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
9. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
11. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
12. Chronic CD70-driven costimulation impairs IgG responses by instructing T cells to inhibit germinal center B cell formation through FasL-Fas interactions.
Beishuizen CR; Kragten NA; Boon L; Nolte MA; van Lier RA; van Gisbergen KP
J Immunol; 2009 Nov; 183(10):6442-51. PubMed ID: 19864607
[TBL] [Abstract][Full Text] [Related]
13. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
[TBL] [Abstract][Full Text] [Related]
14. CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization.
Taraban VY; Rowley TF; Kerr JP; Willoughby JE; Johnson PM; Al-Shamkhani A; Buchan SL
Eur J Immunol; 2013 Dec; 43(12):3314-23. PubMed ID: 24002868
[TBL] [Abstract][Full Text] [Related]
15. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L; Fischmann TO; Wong J; Mauze S; Guadagnoli M; Bąbała N; Wagenaars J; Juan V; Rosen D; Prosise W; Habraken M; Lodewijks I; Gu D; Stammen-Vogelzangs J; Yu Y; Baker J; Lutje Hulsik D; Driessen-Engels L; Malashock D; Kreijtz J; Bertens A; de Vries E; Bovens A; Bramer A; Zhang Y; Wnek R; Troth S; Chartash E; Dobrenkov K; Sadekova S; van Elsas A; Cheung JK; Fayadat-Dilman L; Borst J; Beebe AM; Van Eenennaam H
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100308
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.
Sakanishi T; Yagita H
Biochem Biophys Res Commun; 2010 Mar; 393(4):829-35. PubMed ID: 20171165
[TBL] [Abstract][Full Text] [Related]
18. Ligation of CD27 on murine B cells responding to T-dependent and T-independent stimuli inhibits the generation of plasma cells.
Raman VS; Bal V; Rath S; George A
J Immunol; 2000 Dec; 165(12):6809-15. PubMed ID: 11120803
[TBL] [Abstract][Full Text] [Related]
19. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).
Starzer AM; Berghoff AS
ESMO Open; 2020 Mar; 4(Suppl 3):e000629. PubMed ID: 32152062
[TBL] [Abstract][Full Text] [Related]
20. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Silence K; Dreier T; Moshir M; Ulrichts P; Gabriels SM; Saunders M; Wajant H; Brouckaert P; Huyghe L; Van Hauwermeiren T; Thibault A; De Haard HJ
MAbs; 2014; 6(2):523-32. PubMed ID: 24492296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
